Sato Yakuhin Kogyo Co.

What Sato Yakuhin Kogyo Co. does

Sato Yakuhin Kogyo Co., Ltd. is a Japanese pharmaceutical company founded in 1947 and headquartered in Kashihara, Nara Prefecture, operating a dual business model. The first leg is pharmaceutical contract manufacturing (CMO) services: under GMP certification, the company produces solid oral dosage forms (capsules, tablets, granules) for over 60 domestic Japanese pharmaceutical companies, supporting manufacturing site changes and new product co-development. The second leg is proprietary branded consumer health products marketed under the "Satoyaku" corporate brand, launched in April 2024 alongside a proprietary e-commerce platform (satoyaku.jp). Consumer products span three sub-brands: OTC pharmaceuticals (Thiavitamin B in 2,500+ drugstores, Satoyaku Pharmaceutical Series of cold/analgesic/gastrointestinal drugs); beauty and wellness supplements built on a proprietary liposome technology platform (LIPOCERA White Moist Shot, LIPOCERA CARENINE, Myism Mental Care, BlueTain eye health, MEDIMERRY Kampo-based skincare); and B2B/corporate specialty products (RED-Q salt replacement developed with the Nara Fire Department).

The underlying technology stack is rooted in pharmaceutical manufacturing science rather than digital platforms. Core proprietary capabilities include: (1) liposome encapsulation technology enabling time-differential release of vitamin C in LIPOCERA products; (2) cultivation and extraction of Japanese medicinal herbs (peony, angelica, ginger) through the Wakan Yakugaku Institute in Nara; (3) world-first chestnut-derived human-type ceramides used in MEDIMERRY skincare; (4) GMP-compliant solid dosage form manufacturing for 60+ B2B clients; and (5) ISO14001-certified environmental management. Distribution operates across four channels: proprietary e-commerce (satoyaku.jp), nationwide drugstore chains (2,500+ stores for Thiavitamin B as of April 2025), POPUP retail at Marui department stores in Tokyo/Kobe/Osaka, and direct corporate/organizational sales for B2B heat management products.

Revenue mechanics blend B2B service revenue (CMO contracts) with consumer product revenue (unit pricing ¥500–¥3,780 retail) and corporate/organizational sales for RED-Q. The company employs 501–1,000 people, hired 35 additional employees in April 2026, and remains family-held with no disclosed external investors or public listing. Strategic positioning emphasizes domestic Japanese production, Nara-based heritage, and a "drug's hometown" identity leveraged through multiple government and university partnerships.

Name

Sato Yakuhin Kogyo Co.

Legal name

佐藤薬品工業株式会社 (Sato Yakuhin Kogyo Co., Ltd.)

Website

https://sato-yakuhin.co.jp

Company type

Private

Founded year

1947

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Sato Yakuhin Kogyo Co., Ltd. is a Japanese pharmaceutical company operating a contract manufacturing business (CMO) for 60+ domestic pharma clients and marketing proprietary OTC drugs, supplements, and cosmetics under the "Satoyaku" brand via e-commerce and 2,500+ drugstores nationwide.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing and Consumer Health Products

NAICS

Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210), Medicinal and Botanical Manufacturing (325411)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Cold, Flu, Cough & Allergy Remedies (Decongestants, Antihistamines, Cough Syrups, Lozenges) (CRADAMAD)

akta.pro secondary industry

OTC Medicines & Consumer Health Products Distribution (CRAOAHAB)

Keywords

• Pharmaceutical contract manufacturing
• OTC pharmaceuticals
• Health supplements
• Liposome beauty supplements
• Kampo herbal skincare

Headquarters

HQ city

Kashihara

HQ country

Japan

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Supply Chain, Technology or R&D, Marketing or Sales

Revenue model

1. Contract Manufacturing (受託製造): Contract manufacturing organization (CMO) providing pharmaceutical manufacturing services to 60+ domestic Japanese pharmaceutical companies. Services range from existing product manufacturing site changes to new approved product co-development. Manufacturing solid oral dosage forms including capsules, tablets, and granules.
2. Own Brand OTC Pharmaceuticals and Health Supplements: Sale of proprietary branded pharmaceutical products (OTC drugs including チアビタミン錠B, gastrointestinal medicines, cold remedies, analgesics), health functional foods, and dietary supplements through the company's e-commerce platform and nationwide drugstore distribution.
3. Cosmetics and Skincare (化妆品・护肤品): Sale of proprietary beauty and skincare brands including LIPOCERA (liposome vitamin C supplements), MEDIMERRY (Japanese herbal science skincare), and MEDIMERRY CARENINE (dual care beauty line) through e-commerce and POPUP stores.

Pricing tiers

Go-to-market motion4 records

Distribution channels5 records

Marketing channels9 records

Core offering

Sato Yakuhin Kogyo Co. manufactures pharmaceutical products through two business lines: (1) B2B contract manufacturing of solid oral dosage forms (capsules, tablets, granules) as a domestic top-class CMO serving 60+ Japanese pharmaceutical companies under GMP compliance, and (2) B2C sale of proprietary branded OTC pharmaceuticals, health supplements, liposome beauty supplements, and Japanese herbal skincare under the さとやく (Satoyaku) corporate brand through its own e-commerce platform and 2,500+ drugstore outlets nationwide.

Product overview

Sato Yakuhin Kogyo Co. operates as both a pharmaceutical contract manufacturing organization (CMO) and a consumer health product company. As a CMO, it produces capsules, tablets, and granules for over 60 pharmaceutical clients, adhering to GMP standards. As a brand company, it markets products under the さとやく (Satoyaku) corporate brand through its own e-commerce platform (satoyaku.jp) and national drugstores. The consumer portfolio comprises OTC pharmaceuticals (チアビタミン錠B, さとやく医薬品シリーズ), dietary supplements (LIPOCERA, からだ気配り専科, RED-Q, 爽快決フェチョコビ, メモリーメンテ, Myism), cosmetics/skincare (MEDIMERRY, LIPOCERA CARENINE), and functional foods (ブルーテインクリアサイト, 酵素のおいしい青汁젤리, しょうがパウダー). Pet supplements (ザ・クリアNMN+CoQ10) are also offered. The Wakan Yakugaku Institute supports traditional Japanese medicine research and ingredient cultivation for product development.

Differentiator

Problem solved

Functional benefit

Products and services

• OEM/Contract Manufacturing Services (CMO)
• RED-Q Salt Replacement Supplement
• チアビタミン錠B (Thiavitamin B)
• LIPOCERA White Moist Shot
• LIPOCERA CARENINE Series
• MEDIMERRY Skincare Series
• minttune & OyASUSITORIN (Femcare Products)
• Myism Mental Care Supplement
• BlueTain Clear Site
• Satoyaku Pharmaceutical Series (さとやく医薬品シリーズ)
• 爽快決フェチョコビー (Sokkai Ketsu Fechoco Bee)
• メモリーメンテ タモギタケin健脳GABAゼリー
• しょうがパウダー (Shouga Powder)
• ザ・クリアNMN+CoQ10 (The Clear NMN+CoQ10)
• からだ気配り専科シリーズ (Health Care Series)
• さとやく石鹸 母の日セット (Satoyaku Soap Mother's Day Set)
• さとやくベースボールアカデミー (Satoyaku Baseball Academy)

Quantifiable outcome

• 93% of GINGER magazine readers (30 respondents) expressed intent to continue using LIPOCERA after 30-day trial
• +5 more outcomes

Named customers8 records

Segments5 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Nine partnerships are on record, tiered minor and core.

• Heat Stroke Prevention Calling Project (、熱症予防声かけプロジェクト)minorGTM or Marketing Partner · 1 April 2026Corporate sponsor of the Heat Stroke Prevention Calling Project, a multi-stakeholder initiative involving companies, local governments, and organizations working to promote awareness of hydration and heat management practices. RED-Q packaging carries project logo to raise consumer awareness of heat stroke prevention.
• Mukogawa Women's University, Business Department, Takahashi Seminar (武庫川女子大学経営学部高橋 千枝子ゼミ)coreStrategic or Co-development Partner · 4 March 2026Industry-academia collaboration for co-development of femcare products. Jointly developed minttune feminine zone spray and OyASUSITORIN bust care cream. Student teams led product concept development, packaging design, and market research under Professor Takahashi's supervision. POPUP events held at Namba Marui. Seminar also conducted femcare seminar at the university.
• Nara Prefecture Tourism Promotion (奈良まほろば館)minorGTM or Marketing Partner · 17 February 2026Co-hosted public lecture on Nara's medicinal herb culture and warm-body (温活) practices using ginger at Nara Mahoroba-kan venue in Tokyo. Part of regional cultural promotion linking Nara's pharmaceutical heritage with health product development.
• Osaka Shoin Women's University (大阪樟蔭女子大学)minorGTM or Marketing Partner · 26 November 2025Joint marketing collaboration with the university for Sokka-sei Fe Chocolate (爽快決フェチョコビ) nutritional iron supplement. Co-developed new key visuals and packaging design, with university collaborating on SNS marketing and promoting 'Tetsu-katsu Rhythm' (鉄活リズム) new habit concept for women's iron supplementation awareness.
• Kashihara City Government (橿原市)coreStrategic or Co-development Partner · 28 August 2025Comprehensive regional revitalization partnership covering 10 areas: local production for local consumption, tourism, disaster prevention, elderly/disabled support, women's empowerment and childcare, welfare and health, youth development and education/culture/sports, environment, city PR, and general regional activation. Builds on earlier disaster prevention agreement (February 2024) providing company facilities as temporary evacuation shelters.
• Nara Wide-Area Fire Department (奈良県広域消防組合消防本部)coreStrategic or Co-development Partner · 17 June 2025Comprehensive partnership agreement for fire safety and heat stroke prevention. First joint project: co-development of RED-Q salt replacement supplement for firefighters working in high-temperature environments. Included 3-month monitoring survey with ~200 firefighters. Fire department provided product requirements; Sato Yakuhin applied pharmaceutical formulation expertise.
• Nara Prefecture (Osaka-Kansai Expo Nara Booth) (奈良県)minorGTM or Marketing Partner · 27 May 2025Participated in the Osaka-Kansai Expo 2025 Nara Prefecture exhibition booth for 3 days (May 27-29), showcasing Nara's medicinal herb culture and the company's Wakan Yakuken Institute research and product development. Promoted 'drug's hometown' heritage of Nara Prefecture at a global venue.
• Kindai University, Business Department, Fuse Seminar (近畿大学経営学部布施匡章ゼミ)coreStrategic or Co-development Partner · 6 November 2024Service design-based industry-academia collaboration to research and promote LIPOCERA liposome vitamin C beauty supplement. Student teams designed original recipes and event concepts for POPUP store at Namba Marui. 768 visitors attended 2-day event. Students conducted recipe competition voting (546 participants) and consumer surveys. Collaboration continues with ongoing marketing research projects.
• SME Revitalization Project (中小企業からニッポンを元気にプロジェクト)minorGTM or Marketing Partner · 1 April 2024Participated as Phase 7 member of this national SME revitalization initiative. Actress/influencer Matsui Rena (松井玲奈) serves as project ambassador, and her likeness is used in promotional materials for チアビタミン錠B products.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Nichi-Iko Pharmaceutical Co., Ltd. Major Japanese generic pharmaceutical manufacturer with significant contract manufacturing operations, providing a direct peer comparison for Sato Yakuhin's CMO and generic drug supply business.
• Kobayashi Pharmaceutical Co., Ltd. Leading Japanese OTC and household products company with extensive drugstore distribution and a comparable portfolio of branded supplements, OTC drugs, and skincare. Closest large-cap analog to Sato Yakuhin's mass-market consumer health ambitions.
• Sato Pharmaceutical Co., Ltd. Japanese OTC pharmaceutical manufacturer with overlapping categories including dermatological products, vitamins, and cold remedies. Comparable mid-sized Japanese pharma with branded OTC focus and drugstore distribution.
• Taisho Pharmaceutical Co., Ltd. Major Japanese OTC pharmaceutical manufacturer with a similarly diversified consumer health portfolio spanning cold remedies, vitamins, gastrointestinal drugs, and skincare. Directly comparable to Sato Yakuhin's Satoyaku Pharmaceutical Series and own-brand OTC strategy.
• Daiichi Sankyo Healthcare Co., Ltd. OTC pharmaceutical subsidiary of Daiichi Sankyo, competing directly with Sato Yakuhin in Japanese OTC categories including cold remedies, analgesics, vitamins, and gastrointestinal drugs sold through drugstore chains.
• Bushu Pharmaceuticals Ltd. Japanese pharmaceutical contract manufacturing organization focused on solid dosage forms, providing a direct peer comparison for Sato Yakuhin's CMO service offering and GMP-compliant manufacturing capabilities.
• Nipro Pharma Corporation: Japanese pharmaceutical contract manufacturer with significant CMO operations for both domestic and international pharma clients. Closely comparable to Sato Yakuhin's pharmaceutical manufacturing services business model.
• Towa Pharmaceutical Co., Ltd. Japanese generic pharmaceutical manufacturer with contract manufacturing capabilities serving pharma clients. Directly comparable to Sato Yakuhin's CMO service offering and generic drug portfolio.
• Kowa Company, Ltd. Diversified Japanese pharmaceutical company with a consumer healthcare division producing OTC drugs, supplements, and skincare. Comparable mix of prescription pharma and consumer health products with drugstore distribution.

Broad incumbents

• Otsuka Pharmaceutical Co., Ltd. Larger Japanese pharmaceutical incumbent with substantial OTC, supplement, and skincare brands (including those leveraging proprietary technologies). Operates broader portfolio than Sato Yakuhin but overlaps in consumer health categories.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• Instagraminstagram.com/medimerry_official
• Facebookfacebook.com/profile.php

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sato Yakuhin Kogyo Co.